Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Auranofin reveals therapeutic anticancer potential by triggering distinct molecular cell death mechanisms and innate immunity in mutant p53 non-small cell lung cancer

20 Mar 2021

Abstract excerpt

Auranofin (AF) is an FDA-approved antirheumatic drug with anticancer properties that acts as a thioredoxin reductase 1 (TrxR) inhibitor. The exact mechanisms through which AF targets cancer cells remain elusive. To shed light on the mode of action, this study provides an in-depth analysis on the molecular mechanisms and immunogenicity of AF-mediated cytotoxicity in the non-small cell lung cancer (NSCLC) cell line...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ferroptosis and cancer prognosis
Share to Inflammatory mediators and NSAID effects
Share to RNA modifications and cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33812801
DOI: 10.1016/j.redox.2021.101949

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Auranofin reveals therapeutic anticancer potential by triggering distinct molecular cell death mechanisms and innate immunity in mutant p53 non-small cell lung cancerPMID 33812801Read ↗

Synergistic Dual Targeting of Thioredoxin and Glutathione Systems Irrespective of p53 in Glioblastoma Stem Cells<strong> </strong>Semantic proximity Read ↗

Repurposing auranofin to treat TP53-mutated or PTEN-deleted refractory B-cell lymphomaSemantic proximity Read ↗

Auranofin induces lethality driven by reactive oxygen species in high-grade serous ovarian cancer cellsSemantic proximity Read ↗

Insights Into Ferroptosis, a Novel Target for the Therapy of CancerSemantic proximity Read ↗

Systematic identification of a nuclear receptor-enriched predictive signature for erastin-induced ferroptosisSemantic proximity Read ↗

TP63 drives TKI resistance in EGFR-mutant lung cancer via ferroptosis inhibition.Semantic proximity Read ↗

POLR1A inhibits ferroptosis by regulating TFAM-mediated mitophagy and iron homeostasisSemantic proximity Read ↗

Overview of Ferroptosis and Synthetic Lethality StrategiesSemantic proximity Read ↗

Systematic identification of a nuclear receptor-enriched predictive signature for erastin-induced ferroptosisSemantic proximity Read ↗

Radiation-Induced Lipid Peroxidation Triggers Ferroptosis and Synergizes with Ferroptosis InducersSemantic proximity Read ↗

Ferroptosis response segregates small cell lung cancer (SCLC) neuroendocrine subtypesSemantic proximity Read ↗

In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAFV600E lung adenocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.